Literature DB >> 21424260

Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET.

Sandip Basu, Thomas C Kwee, Drew Torigian, Babak Saboury, Abass Alavi.   

Abstract

Mesh：

Year:  2011        PMID： 21424260     DOI： 10.1007/s00259-011-1766-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

Review 2.  Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.

Authors:  S Sanz-Viedma; D A Torigian; M Parsons; S Basu; A Alavi
Journal:  Rev Esp Med Nucl       Date:  2009 May-Jun

3.  Feasibility of automated partial-volume correction of SUVs in current PET/CT scanners: can manufacturers provide integrated, ready-to-use software?

Authors:  Sandip Basu; Abass Alavi
Journal:  J Nucl Med       Date:  2008-05-15       Impact factor: 10.057

4.  Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey.

Authors:  Michael M Graham; Ramsey D Badawi; Richard L Wahl
Journal:  J Nucl Med       Date:  2011-01-13       Impact factor: 10.057

Review 5.  A new dimension of FDG-PET interpretation: assessment of tumor biology.

Authors:  Thomas C Kwee; Sandip Basu; Babak Saboury; Valentina Ambrosini; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

Review 6.  Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders.

Authors:  Sandip Basu; Babak Saboury; Tom Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

Review 7.  Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.

Authors:  Sandip Basu; Babak Saboury; Drew A Torigian; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

8.  Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.

Authors:  S Basu; J Kung; M Houseni; H Zhuang; G F Tidmarsh; A Alavi
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-03-12       Impact factor: 2.346

9.  Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators.

Authors:  A Alavi; A B Newberg; E Souder; J A Berlin
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

Review 10.  Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states.

Authors:  Sandip Basu; Habib Zaidi; Mohamed Houseni; Gonca Bural; Jay Udupa; Paul Acton; Drew A Torigian; Abass Alavi
Journal:  Semin Nucl Med       Date:  2007-05       Impact factor: 4.446
  10 in total
  5 in total

1.  SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions.

Authors:  Thomas C Kwee; Gang Cheng; Marnix G E H Lam; Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10       Impact factor: 9.236

2.  Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?

Authors:  Laura Gilardi; Concetta De Cicco; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-08       Impact factor: 9.236

3.  Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón; Alberto León Martín; Fernanda Relea Calatayud; María Del Mar Muñoz Sánchez; Miguel Ángel Cruz Mora; Germán Andrés Jiménez Londoño; Ruth Espinosa Aunión
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-18       Impact factor: 9.236

4.  Pre-treatment partial-volume-corrected TLG is the best predictor of overall survival in patients with relapsing/refractory non-hodgkin lymphoma following radioimmunotherapy.

Authors:  Raheleh Taghvaei; Mahdi Zirakchian Zadeh; Reza Sirous; Sara Pourhassan Shamchi; William Y Raynor; Siavash Mehdizadeh Seraj; Mateen Moghbel; Shiyu Wang; Thomas J Werner; Hongming Zhuang; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-12-20

Review 5.  Reinventing Molecular Imaging with Total-Body PET, Part II: Clinical Applications.

Authors:  Babak Saboury; Michael A Morris; Moozhan Nikpanah; Thomas J Werner; Elizabeth C Jones; Abass Alavi
Journal:  PET Clin       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.